Forums

Go Back   Forums > Stock picks and trading strategies

Reply
 
Thread Tools Search this Thread Display Modes
  #1  
Old 11-17-2016,
Agentsmith Agentsmith is offline
Junior Member
 
Join Date: Jun 2009
Posts: 14
Default TSX:EDT / OTC:EDTXF - Spectral Medical Inc.

Financial Review
Revenue for the three months ended March 31, 2016 was $1,062,000 compared to $877,000 for the same three month period last year. First quarter revenues were consistent with prior year levels and this trend is expected to continue for the remainder of the year.
Operating costs for the quarter ended March 31, 2016 were $4,069,000 compared to $3,223,000 in 2015. Most of the Company's expenses are incurred in its Phase III clinical trial and will vary depending on the timing and level of patient enrolment. Apart from clinical trial activities, the Company continues to maintain a low cost operating structure for its base business operations.
Reply With Quote
  #2  
Old 11-19-2016,
AgrikGex AgrikGex is offline
 
Join Date: Dec 2014
Posts: 0
Default

Loss for the quarter ended March 31, 2016 was $2,994,000 ($0.02 per share) compared to $2,322,000 ($0.01 per share) for the same quarter last year.
The Company concluded the first quarter of 2016 with cash on hand of $12,861,000 compared to $6,369,000 as of December 31, 2015.
In February, 2016, the Company closed a bought deal prospectus financing for net proceeds of $9,042,000.
Reply With Quote
  #3  
Old 11-21-2016,
Aidanboog Aidanboog is offline
Junior Member
 
Join Date: Oct 2016
Location: Kenya
Posts: 0
Send a message via ICQ to Aidanboog Send a message via Skype™ to Aidanboog
Default

This Management’s Discussion & Analysis (“MD&A”) for the year ended December 31, 2015 has been prepared to help investors understand the financial performance of the Company in the broader context of the Company’s strategic direction, the risks and opportunities as understood by management, and the key success factors that are relevant to the Company’s performance. Management has prepared this document in conjunction with its broader responsibilities for the accuracy and reliability of the financial statements, as well as the development and maintenance of appropriate information systems and internal controls to ensure that the financial information is complete and reliable. The Finance and Audit Committee of the Board of Directors has reviewed this document and all other publicly reported financial information for integrity, usefulness, reliability and consistency.
Reply With Quote
  #4  
Old 11-23-2016,
aijorpidadf aijorpidadf is offline
 
Join Date: Jun 2014
Location: Belgium
Posts: 0
Send a message via ICQ to aijorpidadf
Default

TORONTO, ONTARIO--(Marketwired - May 31, 2016) - Spectral Medical Inc. ("Spectral" or the "Company"), (TSX:EDT) (OTCQX:EDTXF), a Phase III Company advancing a precision treatment targeting specific patients at high risk of death from septic shock, today announced that it has filed a protocol and is in discussions with the U.S. Food and Drug Administration (FDA) for Expanded Access of Toraymyxin™, the Company's investigational therapeutic hemoperfusion device that removes endotoxin from the bloodstream. The Company also announced several significant updates and milestones achieved on its path to potential regulatory approval and anticipated commercial availability of its treatment in the United States.
Reply With Quote
Reply

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT. The time now is .